A Comparative Study between Conventional and Recent Anticoagulant Therapies in Atrial Fibrillation | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 98, Volume 89, Issue 2, October 2022, Page 6726-6733 PDF (622.06 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2022.270768 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Ekhlas Mohamed Hussein; Mohamed Wafaie Morsi Aboleieneen; Mohammed Mostafa Al-Daydamony; Ali Abd El-fatah Morsi Atwa 
| ||||
| Abstract | ||||
| Background: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, occurring in 1-2% of the general population. With an aging population, its prevalence is estimated to increase two-fold in the next 50 years. The prevalence of AF increases remarkably with age, being 0.5% at 40-50 years of age and 5-15% at 80 years of age. Men are more often affected than women. Objective: This study was aimed to evaluate and compare the healthcare effect and safety of nonvalvular atrial fibrillation (NVAF) patients using novel oral anticoagulants (NOACs) with patients using warfarin. Patients and Methods: This study included a total of 124 patients with non-rheumatic atrial fibrillation on their anticoagulation drug, attending at Department of Cardiology, Zagazig University Hospitals, and Cardiology Clinic, Ministry of Civil Aviation, during the period from 2015 to 2016. Patients were divided into two groups NOACs, group I and warfarin, group II. Results: revealed that there was a statistically significant difference between both groups regarding hemorrhagic complications. The rate of occurrence of hemorrhage among the warfarin group was 8.3% per year compared to 3.3% of the NOACs group. Results revealed also that there was a statistically significant difference between both groups regarding thrombotic complications. The rate of thrombosis among the warfarin group was 25% per year compared to 8.2% of the NOACs group. | ||||
| Keywords | ||||
| It could be concluded that the overall evidence indicates that NOACs could be considered a safe and efficacious alternative to warfarin as a treatment option for atrial fibrillation | ||||
|
Statistics Article View: 147 PDF Download: 216 |
||||
